The case of a person with scleroderma who successfully received a lung transplant from a donor who had tested positive for COVID-19 may predict positive outcomes for other patients, according to a recent report. “To our knowledge this represents the first successful case of lung transplantation of donor lungs…
News
Blood levels of the periostin protein were associated with the degree of skin and cardiac involvement, but not lung or blood vessel involvement, in people with systemic sclerosis (SSc), a study found. Levels of the protein also were higher in patients with diffuse forms of SSc, those living with…
People with systemic scleroderma (SSc) who test positive for cyclic citrullinated peptide (CCP) antibodies are more likely than those who test negative to develop interstitial lung disease (ILD) — when the lungs become scarred — and have worse lung function. That’s according to data from a South Korean study…
The levels of a small RNA molecule called microRNA-27a, or miR-27a, are significantly lower in the blood of women with systemic sclerosis (SSc) compared with healthy women, a study shows. Thus, “MiR-27a could serve as a reliable diagnostic marker for SSc,” researchers wrote, adding that the molecule “could be…
In a real-world study, the systemic sclerosis (SSc) medication RoActemra (tocilizumab) failed to significantly lessen skin and lung scarring compared with standard of care treatment. RoActemra, an approved immunosuppressant therapy for systemic sclerosis-associated interstitial lung disease (SSc-ILD), showed no statistically significant differences in efficacy in treating patients in this…
Sarcopenia, or a loss of muscle mass and strength, occurs in nearly one-quarter of systemic sclerosis (SSc) patients and is linked to a low body mass index (BMI) and high levels of C-reactive protein (CRP), according to a new study in Thailand. Patients with a low BMI —…
Fibroblasts from the skin of people with systemic sclerosis (SSc) can get more energy from their powerhouses, the mitochondria, than healthy skin fibroblasts, a small study found. Researchers zeroed in on some of the molecules that may make for the energy surplus and were able to identify small molecules…
Analyzing the global genetic activity of immune cells called monocytes can identify distinct groups among people with systemic scleroderma, a new study indicates. This type of analysis “may represent a viable mechanism for identifying patients and potentially their response to therapeutics,” its researchers wrote. The study, “…
Tobacco use by systemic sclerosis (SSc) patients is linked to worsening gastrointestinal (GI) symptoms, but the immunosuppressive and anti-scarring medications used to treat the autoimmune disease aren’t, according to a recent analysis of data from a multicenter, U.S.-based patient registry. The findings are striking in light of previous…
People with systemic sclerosis (SSc) have lower-than-normal levels of the SPAG17 protein in their skin cells, which contributes to the excessive scarring that marks the disease, a study suggests. Mice lacking the protein developed signs of scarring, or fibrosis, consistent with that seen in people with SSc, also called scleroderma,…
Recent Posts
- Abnormal fatty acid metabolism may play role in scleroderma: Analysis
- Cosmetic laser therapy could be repurposed for localized scleroderma
- Antibody levels may help reflect quality of life in people with scleroderma
- Certain antibodies tied to poorer outcomes in systemic sclerosis
- Dexamethasone reduces inflammation, scarring in SSc mouse model: Study
- Survival improves for SSc-PAH patients on combination therapy
- Combination drug therapy boosts lung, skin health in SSc patients
- On choosing medicine’s side effects over scleroderma progression
- Telerehabilitation improves hand mobility in scleroderma women
- Molecular pathway ID’d as key driver of scarring in scleroderma